KALA BIO announces 1-for-50 reverse stock split effective May 8, 2026

KALA BIO, Inc.

Reverse stock split at 1-for-50 ratio effective 4:05 p.m. ET on May 8, 2026.
Outstanding shares reduced from 929,491,578 to ~18,589,832; no fractional shares issued.
Cash paid for fractional shares based on May 7 closing price on Nasdaq Capital Market.
Ticker KALA unchanged; split-adjusted trading begins May 11, 2026; new CUSIP 483119301.
Stockholder approved reverse split at January 30, 2026 annual meeting with ratio range of 1-for-2 to 1-for-100.

item 3.03 item 5.03 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Equity Issuances SEC 8-K Item 3.02/3.03 confidence 0.9

KALA BIO, Inc. issued common stock.

Security: common stock

Exact text from the filing

KALA BIO , Inc. (NASDAQ: KALA) (“KALA BIO” or the “Company”), today announced that it intends to effect a reverse stock split of its common stock, par value $0.001 per share (the “common stock”) at a ratio of 1 post-split share for every 50 pre-split shares.

View on SEC.gov

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

KALA BIO, Inc.: Amended the restated certificate of incorporation to effect a 1-for-50 reverse stock split of common stock, effective May 8, 2026 (effective 2026-05-08).

Change: charter amendment
Effective: 2026-05-08

Exact text from the filing

On May 7, 2026, KALA BIO, Inc. (the “ Company ”) filed a Certificate of Amendment (the “ Certificate of Amendment ”) to the Company’s Restated Certificate of Incorporation (as amended, the “ Certificate of Incorporation ”) with the Secretary of State of Delaware to effect a 1-for-50 reverse stock split of the shares of the Company’s common stock, par value $0.001 per share (the “ Common Stock ”), either issued and outstanding or held by the Company as treasury stock, effective as of 4:05 p.m. (Delaware time) on May 8, 2026 (the “ Reverse Stock Split ”).

View on SEC.gov

17 equity issuances filed in the last 30 days. Browse all equity issuances →

KALA BIO, Inc. filing history →

Source: SEC EDGAR

accession 0001829126-26-004744

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.